Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy 2019 | Beyond KarMMa-2: agents targeting BCMA in MM

Andrew Yee • 17 May 2019
COMy 2019
Multiple Myeloma CAR-T
KarMMa-2

Andrew Yee, MD, of Massachusetts General Hospital Cancer Center, Boston, MA, discusses the KarMMa-2 trial (NCT03601078) and further trials that also targeting BCMA. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Andrew Yee

Managing toxicities associated with BCMA-targeting bispecific antibodies in multiple myeloma
1:31
Managing toxicities associated with BCMA-targeting bispecific antibodies in multiple myeloma
Andrew Yee • 17 Sep 2025
AFT-41 trial: daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible NDMM
2:40
AFT-41 trial: daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible NDMM
Andrew Yee • 17 Sep 2025
The transformative impact of BCMA-targeting bispecific antibodies in RRMM
1:12
The transformative impact of BCMA-targeting bispecific antibodies in RRMM
Andrew Yee • 17 Sep 2025
Huge potential for CAR-T therapy in myeloma
2:40
Huge potential for CAR-T therapy in myeloma
Andrew Yee • 17 May 2019

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Andrew Yee • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Andrew Yee • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Andrew Yee • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Andrew Yee • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals